Financhill
Buy
57

GMAB Quote, Financials, Valuation and Earnings

Last price:
$20.14
Seasonality move :
13.13%
Day range:
$19.68 - $20.29
52-week range:
$17.24 - $30.41
Dividend yield:
0%
P/E ratio:
11.57x
P/S ratio:
4.20x
P/B ratio:
2.52x
Volume:
1.8M
Avg. volume:
1.6M
1-year change:
-30.03%
Market cap:
$12.9B
Revenue:
$3.1B
EPS (TTM):
$1.75

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GMAB
Genmab AS
$765.9M $0.23 24.64% -15.88% $29.50
ASND
Ascendis Pharma AS
$107.4M -$1.68 252.37% -30.12% $215.22
GLTO
Galecto
-- -$2.82 -- -51.46% $8.00
JNJ
Johnson & Johnson
$21.6B $2.58 1.86% 38.6% $169.38
NVO
Novo Nordisk AS
$11.9B $0.93 24.06% 34.19% $101.46
ZLDPF
Zealand Pharma AS
$37.9M -- -5.47% -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GMAB
Genmab AS
$20.27 $29.50 $12.9B 11.57x $0.00 0% 4.20x
ASND
Ascendis Pharma AS
$159.13 $215.22 $9.6B -- $0.00 0% 23.51x
GLTO
Galecto
$2.68 $8.00 $3.5M -- $0.00 0% --
JNJ
Johnson & Johnson
$157.75 $169.38 $380.2B 17.55x $1.24 3.14% 4.28x
NVO
Novo Nordisk AS
$59.91 $101.46 $265.9B 18.25x $1.10 2.7% 6.35x
ZLDPF
Zealand Pharma AS
$60.19 -- $4.3B -- $0.00 0% 440.88x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GMAB
Genmab AS
-- 0.325 -- 5.24x
ASND
Ascendis Pharma AS
114.08% 0.580 10.82% 0.81x
GLTO
Galecto
-- 1.132 -- --
JNJ
Johnson & Johnson
33.88% 0.428 -- 0.86x
NVO
Novo Nordisk AS
40.09% 1.361 3.51% 0.52x
ZLDPF
Zealand Pharma AS
3.21% 1.851 0.55% 20.85x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GMAB
Genmab AS
$872.2M $313.1M 23.85% 23.85% 56.76% $353M
ASND
Ascendis Pharma AS
$170.4M $408.3K -69.61% -880.05% -24.36% -$90.9M
GLTO
Galecto
-- -$7.1M -- -- -- -$4.9M
JNJ
Johnson & Johnson
$14.5B $6.2B 20.26% 19.98% 28.32% $4.8B
NVO
Novo Nordisk AS
$10.4B $5.2B 60.28% 86.85% 40.78% -$786.4M
ZLDPF
Zealand Pharma AS
$1.2M -$56.6M -16.68% -17.27% -3128.75% -$24.9M

Genmab AS vs. Competitors

  • Which has Higher Returns GMAB or ASND?

    Ascendis Pharma AS has a net margin of 59.7% compared to Genmab AS's net margin of -22.12%. Genmab AS's return on equity of 23.85% beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.77% $0.85 $5.1B
    ASND
    Ascendis Pharma AS
    91.94% -$0.68 $781.4M
  • What do Analysts Say About GMAB or ASND?

    Genmab AS has a consensus price target of $29.50, signalling upside risk potential of 45.54%. On the other hand Ascendis Pharma AS has an analysts' consensus of $215.22 which suggests that it could grow by 35.25%. Given that Genmab AS has higher upside potential than Ascendis Pharma AS, analysts believe Genmab AS is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    ASND
    Ascendis Pharma AS
    12 1 0
  • Is GMAB or ASND More Risky?

    Genmab AS has a beta of 1.074, which suggesting that the stock is 7.36% more volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.540, suggesting its less volatile than the S&P 500 by 45.961%.

  • Which is a Better Dividend Stock GMAB or ASND?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMAB or ASND?

    Genmab AS quarterly revenues are $920.3M, which are larger than Ascendis Pharma AS quarterly revenues of $185.4M. Genmab AS's net income of $549.4M is higher than Ascendis Pharma AS's net income of -$41M. Notably, Genmab AS's price-to-earnings ratio is 11.57x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.20x versus 23.51x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.20x 11.57x $920.3M $549.4M
    ASND
    Ascendis Pharma AS
    23.51x -- $185.4M -$41M
  • Which has Higher Returns GMAB or GLTO?

    Galecto has a net margin of 59.7% compared to Genmab AS's net margin of --. Genmab AS's return on equity of 23.85% beat Galecto's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.77% $0.85 $5.1B
    GLTO
    Galecto
    -- -$5.23 --
  • What do Analysts Say About GMAB or GLTO?

    Genmab AS has a consensus price target of $29.50, signalling upside risk potential of 45.54%. On the other hand Galecto has an analysts' consensus of $8.00 which suggests that it could grow by 198.51%. Given that Galecto has higher upside potential than Genmab AS, analysts believe Galecto is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    GLTO
    Galecto
    1 1 0
  • Is GMAB or GLTO More Risky?

    Genmab AS has a beta of 1.074, which suggesting that the stock is 7.36% more volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GMAB or GLTO?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMAB or GLTO?

    Genmab AS quarterly revenues are $920.3M, which are larger than Galecto quarterly revenues of --. Genmab AS's net income of $549.4M is higher than Galecto's net income of -$6.7M. Notably, Genmab AS's price-to-earnings ratio is 11.57x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.20x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.20x 11.57x $920.3M $549.4M
    GLTO
    Galecto
    -- -- -- -$6.7M
  • Which has Higher Returns GMAB or JNJ?

    Johnson & Johnson has a net margin of 59.7% compared to Genmab AS's net margin of 50.24%. Genmab AS's return on equity of 23.85% beat Johnson & Johnson's return on equity of 19.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.77% $0.85 $5.1B
    JNJ
    Johnson & Johnson
    66.4% $4.54 $108.1B
  • What do Analysts Say About GMAB or JNJ?

    Genmab AS has a consensus price target of $29.50, signalling upside risk potential of 45.54%. On the other hand Johnson & Johnson has an analysts' consensus of $169.38 which suggests that it could grow by 7.37%. Given that Genmab AS has higher upside potential than Johnson & Johnson, analysts believe Genmab AS is more attractive than Johnson & Johnson.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    JNJ
    Johnson & Johnson
    7 12 0
  • Is GMAB or JNJ More Risky?

    Genmab AS has a beta of 1.074, which suggesting that the stock is 7.36% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

  • Which is a Better Dividend Stock GMAB or JNJ?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.14% to investors and pays a quarterly dividend of $1.24 per share. Genmab AS pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GMAB or JNJ?

    Genmab AS quarterly revenues are $920.3M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Genmab AS's net income of $549.4M is lower than Johnson & Johnson's net income of $11B. Notably, Genmab AS's price-to-earnings ratio is 11.57x while Johnson & Johnson's PE ratio is 17.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.20x versus 4.28x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.20x 11.57x $920.3M $549.4M
    JNJ
    Johnson & Johnson
    4.28x 17.55x $21.9B $11B
  • Which has Higher Returns GMAB or NVO?

    Novo Nordisk AS has a net margin of 59.7% compared to Genmab AS's net margin of 32.95%. Genmab AS's return on equity of 23.85% beat Novo Nordisk AS's return on equity of 86.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.77% $0.85 $5.1B
    NVO
    Novo Nordisk AS
    84.8% $0.91 $33.4B
  • What do Analysts Say About GMAB or NVO?

    Genmab AS has a consensus price target of $29.50, signalling upside risk potential of 45.54%. On the other hand Novo Nordisk AS has an analysts' consensus of $101.46 which suggests that it could grow by 69.35%. Given that Novo Nordisk AS has higher upside potential than Genmab AS, analysts believe Novo Nordisk AS is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    NVO
    Novo Nordisk AS
    4 4 1
  • Is GMAB or NVO More Risky?

    Genmab AS has a beta of 1.074, which suggesting that the stock is 7.36% more volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.645%.

  • Which is a Better Dividend Stock GMAB or NVO?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.7% to investors and pays a quarterly dividend of $1.10 per share. Genmab AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GMAB or NVO?

    Genmab AS quarterly revenues are $920.3M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Genmab AS's net income of $549.4M is lower than Novo Nordisk AS's net income of $4B. Notably, Genmab AS's price-to-earnings ratio is 11.57x while Novo Nordisk AS's PE ratio is 18.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.20x versus 6.35x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.20x 11.57x $920.3M $549.4M
    NVO
    Novo Nordisk AS
    6.35x 18.25x $12.2B $4B
  • Which has Higher Returns GMAB or ZLDPF?

    Zealand Pharma AS has a net margin of 59.7% compared to Genmab AS's net margin of -3213.72%. Genmab AS's return on equity of 23.85% beat Zealand Pharma AS's return on equity of -17.27%.

    Company Gross Margin Earnings Per Share Invested Capital
    GMAB
    Genmab AS
    94.77% $0.85 $5.1B
    ZLDPF
    Zealand Pharma AS
    95.5% -$0.59 $1.2B
  • What do Analysts Say About GMAB or ZLDPF?

    Genmab AS has a consensus price target of $29.50, signalling upside risk potential of 45.54%. On the other hand Zealand Pharma AS has an analysts' consensus of -- which suggests that it could fall by -62.62%. Given that Genmab AS has higher upside potential than Zealand Pharma AS, analysts believe Genmab AS is more attractive than Zealand Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GMAB
    Genmab AS
    4 4 0
    ZLDPF
    Zealand Pharma AS
    0 0 0
  • Is GMAB or ZLDPF More Risky?

    Genmab AS has a beta of 1.074, which suggesting that the stock is 7.36% more volatile than S&P 500. In comparison Zealand Pharma AS has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.219%.

  • Which is a Better Dividend Stock GMAB or ZLDPF?

    Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zealand Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Zealand Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GMAB or ZLDPF?

    Genmab AS quarterly revenues are $920.3M, which are larger than Zealand Pharma AS quarterly revenues of $1.3M. Genmab AS's net income of $549.4M is higher than Zealand Pharma AS's net income of -$41.6M. Notably, Genmab AS's price-to-earnings ratio is 11.57x while Zealand Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.20x versus 440.88x for Zealand Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GMAB
    Genmab AS
    4.20x 11.57x $920.3M $549.4M
    ZLDPF
    Zealand Pharma AS
    440.88x -- $1.3M -$41.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Intel Struggling Against AMD?
Why Is Intel Struggling Against AMD?

Due to its disappointing reports, so-so management, and lack of…

Will PayPal Stock Recover or Keep Sliding?
Will PayPal Stock Recover or Keep Sliding?

Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…

How High Will Eli Lilly Stock Go By 2030?
How High Will Eli Lilly Stock Go By 2030?

The weight loss drugs market is heating up quickly and…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 31x

Sell
42
Is NVDA Stock a Buy?

Market Cap: $2.4T
P/E Ratio: 34x

Alerts

Buy
56
ROOT alert for Apr 23

Root [ROOT] is up 9.37% over the past day.

Buy
72
EFX alert for Apr 23

Equifax [EFX] is up 1.69% over the past day.

Buy
51
CALX alert for Apr 23

Calix [CALX] is down 1.81% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock